Pfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial
Pfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial (NYSE: PFE) today announced that the pivotal Phase 3 BASIS clinical trial (NCT03938792) evaluating marstacimab has met its primary endpoints, having demonstrated statically significant and clinically…
Syneos Health Launches Medical Affairs Digital Amplifier
Syneos Health Launches Medical Affairs Digital Amplifier Syneos Health® (Nasdaq: SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced the launch of Medical Affairs Digital Amplifier, a program designed to drive smarter and more effective scientific exchange. This integrated program…
New WHA resolution to accelerate efforts on food micronutrient fortification
New WHA resolution to accelerate efforts on food micronutrient fortification The delegates at the Seventy-sixth World Health Assembly adopted the resolution on accelerating efforts to prevent micronutrient deficiencies through safe and effective food fortification. The resolution urges Member States to…
76th World Health Assembly adopts first ever resolution on drowning prevention
76th World Health Assembly adopts first ever resolution on drowning prevention Today the 76th World Health Assembly adopted its first ever resolution on drowning prevention requesting governments and their partners, in collaboration with the World Health Organization (WHO), to accelerate action…
New blood biomarker can predict if cognitively healthy elderly will develop Alzheimer’s disease
New blood biomarker can predict if cognitively healthy elderly will develop Alzheimer’s disease Why do some people develop Alzheimer’s disease while others don’t? And, even more puzzlingly, why do many individuals whose brains are chock-full of toxic amyloid aggregates –…
Pfizer Presents Scientific Advancements from its Leading Oncology Portfolio at ASCO 2023 Annual Meeting
Pfizer Presents Scientific Advancements from its Leading Oncology Portfolio at ASCO 2023 Annual Meeting will present data across its Oncology portfolio and growing pipeline, covering multiple tumor types and novel mechanisms of action at the 2023 American Society of Clinical…
Catalent Adds New Cryogenic Capabilities at Shiga, Japan, Facility to Support Clinical Supply Demand for Cell and Gene Therapy Development
Catalent Adds New Cryogenic Capabilities at Shiga, Japan, Facility to Support Clinical Supply Demand for Cell and Gene Therapy Development Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it has…
More ways, to save more lives, for less money: World Health Assembly adopts more Best Buys to tackle noncommunicable diseases
More ways, to save more lives, for less money: World Health Assembly adopts more Best Buys to tackle noncommunicable diseases The World Health Organization has expanded the list of ‘NCD best buys’. The updated list was approved at the 76th World…
WHO urges governments to stop subsidizing life-threatening tobacco crops
WHO urges governments to stop subsidizing life-threatening tobacco crops On World No Tobacco Day, WHO urges governments to stop subsidizing tobacco farming and support more sustainable crops that could feed millions. “Tobacco is responsible for 8 million deaths a year, yet…
Bolivia conducts a simulation exercise to strengthen the National Deployment and Vaccination Plan for influenza and other respiratory viruses
Bolivia conducts a simulation exercise to strengthen the National Deployment and Vaccination Plan for influenza and other respiratory viruses As part of a series of twelve workshops to identify lessons learned from COVID-19 and to develop a pandemic preparedness plan…
Ultomiris approved in Japan for the prevention of relapses in patients with neuromyelitis optica spectrum disorder (NMOSD)
Ultomiris approved in Japan for the prevention of relapses in patients with neuromyelitis optica spectrum disorder (NMOSD) Ultomiris (ravulizumab) has been approved in Japan as the first and only long-acting C5 complement inhibitor for the prevention of relapses in patients with…
Imfinzi plus Lynparza and Imfinzi alone both significantly improved progression-free survival in advanced endometrial cancer when added to chemotherapy
Imfinzi plus Lynparza and Imfinzi alone both significantly improved progression-free survival in advanced endometrial cancer when added to chemotherapy Positive high-level results from the DUO-E Phase III trial showed Imfinzi (durvalumab) in combination with platinum-based chemotherapy followed by either Imfinzi plus Lynparza (olaparib)or Imfinzi alone as maintenance therapy…